NCT05704556View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
Pain
Interventions
DRUG

VX-548

Tablets for oral administration.

Trial Locations (7)

32720

Infigo Clinical Research, DeLand

33603

Genesis Clinical Research, Tampa

33618

Elixia, Phase 1 Clinical Site, Tampa

33705

GCP Research, St. Petersburg

77099

Southwest Houston Research, Ltd, Houston

78229

Clinical Trials of Texas, LLC, San Antonio

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT05704556 - Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | Biotech Hunter | Biotech Hunter